基本情報
- CAS
627085-11-4- 標準SMILES
CC1(C)CC(OC(=O)C2CC2)CC(C)(C)N1O- InChIKey
ZWEXEKJLDHNLLA-UHFFFAOYSA-N- 分子式
- C13H23NO3
- 平均分子量
- 241.33 g/mol
- 単同位体質量
- 241.1677936
概要
OT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. It is intended to treat Age-related macular Degeneration (AMD), and preclinical research results indicate additional uses for OT-551, including treatment of early stage and advanced dry age-related macular degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD. A leading cause of vision loss, AMD affects approximately 10 million Americans.
名称と識別子
- 優先名称
- Ot-551
- IUPAC
- (1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate
- 英語名
- Cyclopropanecarboxylic acid, 1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl ester
- 分子式
- C13H23NO3
- 分子量
- 241.33
名称と別名
OT-551627085-11-4DZ02S3A31NCyclopropanecarboxylic acid, 1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl ester1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl cyclopropanecarboxylateRefChem:168700UNII-DZ02S3A31NOT 551(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl) cyclopropanecarboxylate1-Piperidinyloxy, 4-[(cyclopropylcarbonyl)oxy]-2,2,6,6-tetramethyl-627085-14-7627085-11-4 (free base)
名称をさらに表示
CPC551CPC-551CPC 551
OT-551 (free base)orb1699738SCHEMBL3692374CHEMBL4297313ZWEXEKJLDHNLLA-UHFFFAOYSA-NAKOS040749100DB05650CS-0025789
データベース識別子
- CAS
627085-11-4- PubChem CID
- 10131000
- ChEMBL
CHEMBL4297313- UNII
- DZ02S3A31N
物性
構造計算による物性
- XLogP
- 1.9
- 極性表面積
- 49.8 Ų
- 水素結合供与体数
- 1
- 水素結合受容体数
- 4
- 回転可能結合数
- 3
- 重原子数
- 17
- 形式電荷
- 0
- 複雑度
- 303
実験および物理化学的性質
DrugsPharmaceuticals -> Listed in ZINC15
物理化学的性質
- 沸点
- 318.4 · 318.4±31.0 °C(Predicted)
- 比重(密度)
- 1.12 · 1.12±0.1 g/cm3(Predicted)
- 酸解離定数(Pka)
- 13.76 · 13.76±0.70(Predicted)
化学と産業
薬理情報
PharmacodynamicsOT-551, which has been shown to be a potent catalytic antioxidant, recently completed a Phase 1 safety and comfort study in healthy volunteers.
サプライヤー4 社
欧利希（湖北）医药科技有限公司17316404525 17316404525 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
上海陶术生物科技股份有限公司13564774135 · [email protected]
TargetMol中国（陶术生物）15002134094 · [email protected]
関連反応
4 件
化合物ノート
読み込み中…